Darwish et al. and Kamal et al. both reported TIM-3 as a biomarker of poor prognosis in AML, while Xu et al. reported that increased TIM-3 expression correlated with low-risk group and higher complete remission rate in newly diagnosed non-M3 AML patients (15–17). This evidence concerns the gene HAVCR2 and acute myeloid leukemia.